Linical Co., Ltd. Announces the Establishment of an Affiliate Company in Shanghai, People’s Republic of China
June 05, 2019 at 10:30 pm EDT
Share
Linical Co., Ltd. announced that it has completed procedures for the establishment of a wholly owned subsidiary in Shanghai, China on 28 May 2019. The Linical group is advancing its global strategy by expanding its network and business overseas in the United States, Europe, and Asia in order to deliver a one-stop comprehensive service to the company's clients around the world. Linical has an affiliate company in Beijing, China since the acquisition of Accelovance Inc. last year. Linical Accelovance China Ltd. (Beijing, hereinafter "LAC") has been conducting business in China. LAC has been entrusted with several clinical trials from Japanese and European pharmaceutical companies. In order to respond to the increasing need for clinical trials in China and to enhance client satisfaction in speed, quality and convenience, Linical China Co., Ltd. has been established in Shanghai, China. Demand for clinical trials in China is expected to continue to increase. The establishment of Shanghai office, together with the existing Beijing office, expands the coverage to a wider range of business territory in China. The optimal organization structure in China will be examined in the medium to long term. Company name is Linical China Co., Ltd. Location is Room 31, 26F Lippo Plaza, 222 Middle Huaihai Road, Huangpu District, Shanghai, people's republic of China. Main business lines is CRO business. Establishment date is 28 May 2019.
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.